Liaoning Yiling Kechuang Biopharmaceutical Technology

Liaoning Yiling Kechuang Biopharmaceutical Technology is a Chinese biotechnology company specializing in the research and development of innovative pharmaceutical formulations and medical solutions. Based in Liaoning province, the company focuses on therapeutic areas such as cardiovascular health, hepatology, and infectious diseases. Its portfolio includes a myocardial viscera preservative fluid for organ protection, a triple-combination therapy for hyperlipidemia (ezetimibe, simvastatin, and nicotinic acid), and research into ursodeoxycholic acid (UDCA). The company has been recognized for its participation in China's National Major New Drug Discovery program and maintains strategic partnerships for technology development. Led by General Manager Guan Yi, Liaoning Yiling Kechuang utilizes advanced formulation technologies like melt extrusion to improve drug stability and therapeutic outcomes.